Published in Eur J Pharmacol on July 14, 1999
CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 2.74
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia (2010) 1.70
Cannabinoids and neuroinflammation. Br J Pharmacol (2004) 1.62
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol (2005) 1.60
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol (2001) 1.49
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol (2003) 1.47
Endocannabinoid signaling in microglial cells. Neuropharmacology (2008) 1.36
Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav (2009) 1.29
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One (2008) 1.26
Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A (2014) 1.13
Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci (2008) 1.12
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci (2010) 1.04
CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol (2011) 1.02
Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors. Br J Pharmacol (2012) 1.02
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci (2009) 1.01
Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci (2012) 1.00
The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. Br J Pharmacol (2007) 0.92
Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356). Psychopharmacology (Berl) (2006) 0.92
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci (2011) 0.91
Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS. Curr Neuropharmacol (2011) 0.90
Pharmacological characterisation of place escape/avoidance behaviour in the rat chronic constriction injury model of neuropathic pain. Psychopharmacology (Berl) (2006) 0.87
Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. Psychopharmacology (Berl) (2004) 0.87
Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology (Berl) (2013) 0.83
Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem J (2005) 0.82
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct (2014) 0.81
Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats. Behav Pharmacol (2014) 0.81
'Macrophage' cannabinoid receptor goes up in smoke. Nat Neurosci (2011) 0.77
Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders. Pharmaceuticals (Basel) (2010) 0.76
Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues. Br J Pharmacol (2001) 0.75
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
Regulation of adipose tissue pyruvate dehydrogenase by insulin and other hormones. Biochem J (1971) 4.50
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem J (1972) 4.05
Risk factors in dengue shock syndrome. Am J Trop Med Hyg (1997) 3.83
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A (1999) 3.54
Improved lactose digestion and intolerance among African-American adolescent girls fed a dairy-rich diet. J Am Diet Assoc (2000) 2.94
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther (1996) 2.90
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther (2000) 2.26
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 2.22
Role of adenine and guanine nucleotides in the activity and response of adenylate cyclase systems to hormones: evidence for multisite transition states. Adv Cyclic Nucleotide Res (1975) 2.06
Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther (2008) 2.04
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem (2000) 2.04
Mechanisms regulating adipose-tissue pyruvate dehydrogenase. Biochem J (1972) 2.01
Continuous infusion of pyridostigmine in the management of myasthenic crisis. Crit Care Med (1993) 1.99
Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene (1997) 1.98
Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther (1998) 1.97
Cannabis: pharmacology and toxicology in animals and humans. Addiction (1996) 1.89
Distinct patterns of DeltaFosB induction in brain by drugs of abuse. Synapse (2008) 1.87
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther (1997) 1.87
In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther (1996) 1.85
Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene (2006) 1.82
Nicotine dependence and reward differ between adolescent and adult male mice. J Pharmacol Exp Ther (2007) 1.81
Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (1992) 1.76
Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature (1997) 1.76
Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol (1996) 1.75
Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension (1997) 1.75
3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem (1999) 1.73
Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol (1995) 1.72
Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther (2003) 1.64
Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther (1988) 1.58
Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther (1996) 1.55
Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend (2000) 1.55
Functional homology between signal-coupling proteins. Cholera toxin inactivates the GTPase activity of transducin. J Biol Chem (1982) 1.53
Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther (2000) 1.52
Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther (1994) 1.52
Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol (2006) 1.48
A simple enzymic method for the synthesis of adenosine 5'-[alpha-32P]triphosphate on a preparative scale. Biochem J (1977) 1.47
TCR-CD56+CD2+ nasal lymphomas with membrane-localized CD3 positivity: are the CD3+ cells neoplastic or reactive? Blood (1995) 1.47
Evidence that the antinociceptive tail-flick response is produced independently from changes in either tail-skin temperature or core temperature. Pain (1993) 1.46
Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther (1992) 1.41
Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther (2005) 1.39
Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) (1995) 1.38
Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther (1998) 1.37
Cost and survival results of critical care regionalization for Medicare patients. Crit Care Med (1989) 1.37
Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem Pharmacol (1997) 1.36
Cannabinoid tolerance and dependence. Handb Exp Pharmacol (2005) 1.35
Insulin inhibits the cholera-toxin-catalysed ribosylation of a Mr-25000 protein in rat liver plasma membranes. Biochem J (1985) 1.35
Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer (2007) 1.33
Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer (1996) 1.32
Racial differences in bone turnover and calcium metabolism in adolescent females. J Clin Endocrinol Metab (2003) 1.31
Insulin activates pyruvate dehydrogenase in rat epididymal adipose tissue. Nat New Biol (1971) 1.31
Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther (1998) 1.31
Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol (1992) 1.30
Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol (2001) 1.29
The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neuropharmacology (2000) 1.28
Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther (1995) 1.28
Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther (2001) 1.27
Metabolism of pyruvate and malate by isolated fat-cell mitochondria. Biochem J (1971) 1.26
Effects of insulin and adrenaline on rat epididymal-fat-pad pyruvate dehydrogenase. Biochem J (1971) 1.26
Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) (1996) 1.25
ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta4. Oncogene (2010) 1.24
Soy isoflavones do not affect bone resorption in postmenopausal women: a dose-response study using a novel approach with 41Ca. J Clin Endocrinol Metab (2006) 1.24
The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther (1997) 1.24
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. J Clin Endocrinol Metab (2009) 1.22
Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther (1998) 1.22
DNA methylation and the Epstein-Barr virus. Semin Cancer Biol (1999) 1.21
Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene (2007) 1.21
The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes. J Med Chem (1998) 1.20
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem (1996) 1.19
The effect of insulin on plasma-membrane and mitochondrial-membrane potentials in isolated fat-cells. Biochem J (1981) 1.19
Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend (1995) 1.18
Calcium retention in relation to calcium intake and postmenarcheal age in adolescent females. Am J Clin Nutr (1997) 1.17
Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther (1998) 1.16
Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend (2000) 1.16
Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther (1991) 1.16
Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene (2008) 1.16
Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav (1989) 1.15
Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. J Pharmacol Exp Ther (1982) 1.15
Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol Biochem Behav (1990) 1.15
Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J Pharmacol Exp Ther (1999) 1.15
The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol (2007) 1.13